Battle royale: Systemic versus locoregional therapy for unresectable hepatocellular carcinoma

Research output: Contribution to journalReview article


OBJECTIVE. This commentary discusses research examining comparisons of locoregional therapy with systemic therapy for unresectable hepatocellular carcinoma (HCC). CONCLUSION. Comparison of patient outcomes after locoregional or systemic therapy for HCC is confounded by selection bias, wherein patients chosen for locoregional therapy usually have better underlying liver function that may contribute to the observed longer survival.

Original languageEnglish (US)
Pages (from-to)1366-1367
Number of pages2
JournalAmerican Journal of Roentgenology
Issue number6
Publication statusPublished - Jun 1 2018



  • Chemoembolization, hepatocellular carcinoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this